Cargando…

Muscle damage in patients with neuromyelitis optica spectrum disorder

OBJECTIVE: Increasing evidence has shown that skeletal muscle damage plays a role in neuromyelitis optica spectrum disorder (NMOSD). The objective of this study was to compare the serum creatine kinase (sCK) levels in NMOSD patients with different clinical statuses. METHODS: In the observational stu...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Hong-xi, Zhang, Qin, Lian, Zhi-yun, Liu, Ju, Shi, Zi-yan, Miao, Xiao-hui, Feng, Hui-ru, Du, Qin, Xie, Jing-lu, Yao, Shao-li, Zhou, Hong-yu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5608564/
https://www.ncbi.nlm.nih.gov/pubmed/28955716
http://dx.doi.org/10.1212/NXI.0000000000000400
_version_ 1783265455694151680
author Chen, Hong-xi
Zhang, Qin
Lian, Zhi-yun
Liu, Ju
Shi, Zi-yan
Miao, Xiao-hui
Feng, Hui-ru
Du, Qin
Xie, Jing-lu
Yao, Shao-li
Zhou, Hong-yu
author_facet Chen, Hong-xi
Zhang, Qin
Lian, Zhi-yun
Liu, Ju
Shi, Zi-yan
Miao, Xiao-hui
Feng, Hui-ru
Du, Qin
Xie, Jing-lu
Yao, Shao-li
Zhou, Hong-yu
author_sort Chen, Hong-xi
collection PubMed
description OBJECTIVE: Increasing evidence has shown that skeletal muscle damage plays a role in neuromyelitis optica spectrum disorder (NMOSD). The objective of this study was to compare the serum creatine kinase (sCK) levels in NMOSD patients with different clinical statuses. METHODS: In the observational study, levels of sCK were measured during the acute and stable phases for patients with NMOSD and healthy controls (HCs). RESULTS: We enrolled 168 patients with NMOSD (female:male ratio, 153:15; age: 43.9 ± 13.1 years) in the acute phase, and blood samples were collected from 85 of the patients with NMOSD during both acute and stable phases to determine the sCK levels. The mean log sCK levels of the patients with NMOSD in the acute phase were higher (4.51 ± 1.17, n = 85) than those of the patients with NMOSD in the stable phase (3.85 ± 0.81, n = 85, p = 0.000). Furthermore, the log sCK levels of the patients with NMOSD in the stable phase were lower than those of the HCs (4.31 ± 0.39, n = 200, p = 0.000). In patients with sCK levels within the normal limits, these differences were also observed (p < 0.05). In the multivariable linear regression model performed for the patients with NMOSD in the acute phase, it suggested that a higher estimated glomerular filtration rate (p = 0.026), patients with the core clinical characteristics of optic neuritis (p = 0.005), and serum anti-SSA positivity (p = 0.019) predicted lower log sCK levels. CONCLUSIONS: Muscle damage occurs in patients with NMOSD and is aggravated during the acute phase.
format Online
Article
Text
id pubmed-5608564
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-56085642017-09-27 Muscle damage in patients with neuromyelitis optica spectrum disorder Chen, Hong-xi Zhang, Qin Lian, Zhi-yun Liu, Ju Shi, Zi-yan Miao, Xiao-hui Feng, Hui-ru Du, Qin Xie, Jing-lu Yao, Shao-li Zhou, Hong-yu Neurol Neuroimmunol Neuroinflamm Article OBJECTIVE: Increasing evidence has shown that skeletal muscle damage plays a role in neuromyelitis optica spectrum disorder (NMOSD). The objective of this study was to compare the serum creatine kinase (sCK) levels in NMOSD patients with different clinical statuses. METHODS: In the observational study, levels of sCK were measured during the acute and stable phases for patients with NMOSD and healthy controls (HCs). RESULTS: We enrolled 168 patients with NMOSD (female:male ratio, 153:15; age: 43.9 ± 13.1 years) in the acute phase, and blood samples were collected from 85 of the patients with NMOSD during both acute and stable phases to determine the sCK levels. The mean log sCK levels of the patients with NMOSD in the acute phase were higher (4.51 ± 1.17, n = 85) than those of the patients with NMOSD in the stable phase (3.85 ± 0.81, n = 85, p = 0.000). Furthermore, the log sCK levels of the patients with NMOSD in the stable phase were lower than those of the HCs (4.31 ± 0.39, n = 200, p = 0.000). In patients with sCK levels within the normal limits, these differences were also observed (p < 0.05). In the multivariable linear regression model performed for the patients with NMOSD in the acute phase, it suggested that a higher estimated glomerular filtration rate (p = 0.026), patients with the core clinical characteristics of optic neuritis (p = 0.005), and serum anti-SSA positivity (p = 0.019) predicted lower log sCK levels. CONCLUSIONS: Muscle damage occurs in patients with NMOSD and is aggravated during the acute phase. Lippincott Williams & Wilkins 2017-09-13 /pmc/articles/PMC5608564/ /pubmed/28955716 http://dx.doi.org/10.1212/NXI.0000000000000400 Text en Copyright © 2017 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND) (http://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
spellingShingle Article
Chen, Hong-xi
Zhang, Qin
Lian, Zhi-yun
Liu, Ju
Shi, Zi-yan
Miao, Xiao-hui
Feng, Hui-ru
Du, Qin
Xie, Jing-lu
Yao, Shao-li
Zhou, Hong-yu
Muscle damage in patients with neuromyelitis optica spectrum disorder
title Muscle damage in patients with neuromyelitis optica spectrum disorder
title_full Muscle damage in patients with neuromyelitis optica spectrum disorder
title_fullStr Muscle damage in patients with neuromyelitis optica spectrum disorder
title_full_unstemmed Muscle damage in patients with neuromyelitis optica spectrum disorder
title_short Muscle damage in patients with neuromyelitis optica spectrum disorder
title_sort muscle damage in patients with neuromyelitis optica spectrum disorder
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5608564/
https://www.ncbi.nlm.nih.gov/pubmed/28955716
http://dx.doi.org/10.1212/NXI.0000000000000400
work_keys_str_mv AT chenhongxi muscledamageinpatientswithneuromyelitisopticaspectrumdisorder
AT zhangqin muscledamageinpatientswithneuromyelitisopticaspectrumdisorder
AT lianzhiyun muscledamageinpatientswithneuromyelitisopticaspectrumdisorder
AT liuju muscledamageinpatientswithneuromyelitisopticaspectrumdisorder
AT shiziyan muscledamageinpatientswithneuromyelitisopticaspectrumdisorder
AT miaoxiaohui muscledamageinpatientswithneuromyelitisopticaspectrumdisorder
AT fenghuiru muscledamageinpatientswithneuromyelitisopticaspectrumdisorder
AT duqin muscledamageinpatientswithneuromyelitisopticaspectrumdisorder
AT xiejinglu muscledamageinpatientswithneuromyelitisopticaspectrumdisorder
AT yaoshaoli muscledamageinpatientswithneuromyelitisopticaspectrumdisorder
AT zhouhongyu muscledamageinpatientswithneuromyelitisopticaspectrumdisorder